A Phase 3 clinical trial investigating retatrutide (LY3437943) in participants with obesity or overweight and osteoarthritis of the knee completed its primary study period on 2025-11-14. This marks a significant milestone for the study (NCT05931367), which aims to evaluate the safety and efficacy of once-weekly retatrutide.
Background
Retatrutide, also known by its investigational identifier LY3437943, is being studied for its potential in managing conditions such as obesity, overweight, and osteoarthritis of the knee.
Trial design
The study, identified as NCT05931367, is a Phase 3 trial with an enrollment of 445 participants. It investigates retatrutide once weekly in individuals diagnosed with obesity or who are overweight and also have osteoarthritis of the knee. The trial includes retatrutide and placebo as interventions, with the main purpose to evaluate their safety and efficacy. The study duration is approximately 77 weeks.
What this means
The primary completion of this Phase 3 trial indicates that all participants have finished the main intervention period and data collection for the primary endpoints is complete. This step is crucial for the subsequent analysis of the trial's safety and efficacy data for retatrutide in the specified patient population. The findings from this study will be important for understanding the potential role of retatrutide in managing weight and knee osteoarthritis.
Source
The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The status for study NCT05931367, titled "A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee," was updated on 2025-11-14 on clinicaltrials.gov.